For the quarter ending 2025-09-30, REVB had $6,209,471 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -6,402,643 |
| Stock-based compensation expense | 225,202 |
| Depreciation expense | 21,206 |
| Loss on disposal of equipment | -11,207 |
| Change in fair value of warrant liability | -2,071 |
| Prepaid expenses and other current assets | 57,235 |
| Accounts payable | 236,330 |
| Accrued expenses | -334,585 |
| Net cash used in operating activities | -6,302,589 |
| Proceeds from public offering, net-May2025Public Offering | 3,388,244 |
| Proceeds from warrant exercise-Class HPre Funded Warrants | 297 |
| Proceeds from warrant exercise-Warrant Inducement | 8,760,519 |
| Proceeds from warrant exercise-Class HWarrants | 363,000 |
| Net cash provided by financing activities | 12,512,060 |
| Net increase (decrease) in cash and cash equivalents | 6,209,471 |
| Cash and cash equivalents at beginning of period | 6,499,018 |
| Cash and cash equivalents at end of period | 12,708,489 |
REVELATION BIOSCIENCES, INC. (REVB)
REVELATION BIOSCIENCES, INC. (REVB)